These upgrades will enable advanced development and flexible manufacturing, supporting complex therapeutics and meeting global demand for advanced pharmaceutical solutions
The Taipei facility boasts 10 GMP API production lines, with a total reactor volume exceeding 350,000 liters
The move comes as the global biotech and biopharma CDMO market continues to surge, fueled by rising demand
The new equipment will be installed at Codis’ 400,000-square-foot Haverhill facility and is expected to be operational by 2027
Investment marks continued progress against AbbVie's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade
The program seeks to boost regulatory predictability, support construction of US-based manufacturing sites
A nationwide network of over 1,000 accredited clinical trial sites will be created to accelerate drug development timelines and enhance research credibility
The facility will bring 850 high-value jobs to the region, including engineers, scientists, operations personnel, and lab technicians
The state-of-the-art commercial production plant will be built on a 95-acre site in Saarlouis, acquired at the end of 2024
Subscribe To Our Newsletter & Stay Updated
